Eversept Partners LP Purchases 26,179 Shares of Biogen Inc. $BIIB

Eversept Partners LP raised its position in Biogen Inc. (NASDAQ:BIIB) by 50.6% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 77,944 shares of the biotechnology company’s stock after acquiring an additional 26,179 shares during the period. Eversept Partners LP owned about 0.05% of Biogen worth $13,717,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. WPG Advisers LLC lifted its stake in Biogen by 417.9% in the 4th quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock valued at $26,000 after acquiring an additional 117 shares in the last quarter. Accredited Wealth Management LLC lifted its stake in Biogen by 1,233.3% in the 3rd quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 185 shares in the last quarter. First Horizon Corp bought a new stake in Biogen in the 4th quarter valued at approximately $30,000. WFA of San Diego LLC bought a new stake in Biogen in the 2nd quarter valued at approximately $32,000. Finally, Root Financial Partners LLC lifted its stake in Biogen by 198.4% in the 4th quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 123 shares in the last quarter. Institutional investors own 87.93% of the company’s stock.

Biogen Stock Up 1.6%

NASDAQ:BIIB opened at $198.67 on Thursday. The firm has a market capitalization of $29.33 billion, a price-to-earnings ratio of 21.32 and a beta of 0.20. Biogen Inc. has a twelve month low of $121.05 and a twelve month high of $205.97. The stock’s 50 day moving average price is $190.05 and its two-hundred day moving average price is $184.70. The company has a quick ratio of 2.41, a current ratio of 3.06 and a debt-to-equity ratio of 0.34.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share for the quarter, topping the consensus estimate of $2.95 by $0.62. The firm had revenue of $2.48 billion for the quarter, compared to analyst estimates of $2.29 billion. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The business’s quarterly revenue was up 1.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.02 EPS. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Equities research analysts expect that Biogen Inc. will post 13.89 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have commented on BIIB. Argus upgraded Biogen to a “hold” rating in a research note on Thursday, April 9th. HC Wainwright restated a “buy” rating on shares of Biogen in a research note on Thursday, May 14th. Canaccord Genuity Group boosted their price target on Biogen from $230.00 to $245.00 and gave the stock a “buy” rating in a research report on Wednesday, April 1st. Wall Street Zen raised Biogen from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Finally, Guggenheim boosted their price target on Biogen from $246.00 to $260.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Biogen presently has an average rating of “Moderate Buy” and an average price target of $216.70.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.